bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Access the interviews in their entirety at:
In an exclusive interview, Maria Zannes, President and CEO of bioAffinity, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate update. bioAffinity addresses the urgent need for noninvasive, accurate early-stage cancer diagnosis through its first product, CyPath® Lung. CyPath® Lung improves early-stage detection of lung cancer, leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs. In October 2024, bioAffinity secured a U.S. Federal Supply Schedule contract for CyPath® Lung, making the test available to U.S. veterans and federal health service patients, which is expected to accelerate sales growth in the quarters ahead.
Motti Farbstein, Chief Executive Officer of Can-Fite, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's current development pipeline and upcoming milestones. Strategically positioned with multiple out-licensing deals and potential regulatory and sales milestone payments totaling over $130 million, Can-Fite has already received $20 million in upfront and milestone payments, underscoring the potential of its therapies. With advanced-stage assets targeting unmet medical needs in markets with a combined value in excess of $70 billion, Can-Fite believes that it is well positioned for the potential commercialization of its innovative therapies.
BIAF and CANF are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson reported topline results in a Phase III trial for psoriasis and commenced a pivotal Phase III trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase IIb trial for the treatment of MASH, and in a Phase IIa study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: https://www.canfite.com/.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
Contact:
Dave Gentry
RedChip Companies Inc.
1-407-644-4256
--END--
SOURCE: RedChip Companies, Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
12 minutes ago
- Business Wire
1031 Crowdfunding Ranks No. 2886 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
IRVINE, Calif.--(BUSINESS WIRE)-- Inc. revealed that 1031 Crowdfunding ranks No. 2886 on the 2025 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy's most dynamic segment—its independent, entrepreneurial businesses. This achievement underscores the value we deliver to our investors and the strength of the platform we've built. Share 'We're thrilled to be included on the Inc. 5000 list,' says Edward Fernandez, President and CEO of 1031 Crowdfunding. 'This achievement underscores the value we deliver to our investors and the strength of the platform we've built. As we continue to scale, we remain committed to providing institutional-quality real estate investments that drive long-term value for our investors.' Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. The list represents companies that have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. For complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, location, and other criteria, go to Methodology Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. About 1031 Crowdfunding 1031 Crowdfunding is a private equity real estate investment and asset management firm. Our online marketplace provides a wide range of alternative investment vehicles focused on tax deferral. The properties listed on our marketplace are vetted and generally already purchased which mitigates closing risk. This convenient system helps many of our clients close within three to five days. Our innovative platform and industry expertise make it easy for investors to find and purchase real estate that aligns with their financial goals. For more information, visit or call 844-533-1031.
Business Wire
12 minutes ago
- Business Wire
Heritage Global Partners to Conduct Court-Approved Auction of CaaStle, Inc.'s Clothing Inventory and Industrial Laundry Equipment
SAN DIEGO--(BUSINESS WIRE)--Heritage Global Partners ('HGP'), a subsidiary of Heritage Global Inc. (NASDAQ: HGBL) and a worldwide leader in asset advisory and auction services, has been appointed by the U.S. Bankruptcy Court for the District of Delaware, (Case #1:25-bk-11187), to conduct an online auction of assets formerly owned by CaaStle, Inc., a tech-enabled B2B clothing logistics company. Auction Details: This large-scale sale features commercial laundry systems, warehouse infrastructure, and a significant quantity of premium branded clothing inventory, providing an opportunity for secondary market retailers, commercial laundry operators, 3PL/logistics providers, and apparel resellers to acquire high-value equipment and merchandise. Featured Assets Include: Apparel inventory from Ralph Lauren, Ba&sh, Maje, Ann Taylor, Banana Republic, and more (8) Realstar KM803 Dry Cleaning Systems (7) Wascomat EX677CL Commercial Washing Machines Wascomat EX645CL Commercial Washing Machines (6) Wascomet D783 Commercial Washing Machines (12) Wascomat TD83 Commercial Dryers (4) Leonard IM96SH Steam Tunnel Systems (300+) Garment Racks Pallet Racking (50+) Zebra Label Printers (ZD420, ZT410 models) JLG ES3246 Electric Scissor Lift Raymond R40 Reach Truck (150+) Uline Vinyl Basket Trucks (150+) Uline Poly Box Trucks And much more 'This auction includes a comprehensive offering of late-model commercial laundry systems and thousands of high-quality apparel units from top-tier brands,' said David Barkoff, Senior Vice President at Heritage Global Partners. 'We believe this rare opportunity represents an ideal sale for buyers across fashion resale, logistics, and textile services looking for well-maintained, ready-to-deploy assets.' Heritage Global Partners, Inc. ('HGP') HGP is a subsidiary of Heritage Global Inc. (NASDAQ: HGBL). HGP operates under the Industrial Assets business unit and is a full-service auction, liquidation and asset advisory firm which holds a prominent spot in the industrial sectors including Aerospace, Automotive, Aviation, Biotech, Broadcast & Postproduction, Chemical, Electronics Manufacturing, Energy, Food & Beverage, Heavy Construction, Metalworking, Oil & Gas, Pharmaceutical, Plastics, Printing, Real estate, Semiconductor, Solar, Textile & Woodworking, and others. HGP conducts 150-200 auction projects per year, globally. Heritage Global Inc. ('HG') HG values and monetizes industrial & financial assets by providing acquisition, disposition, valuation, and lending services for surplus and distressed assets. This aids in facilitating the circular economy by diverting useful industrial assets from landfills and operating an ethical supply chain by overseeing post-sale account activity of financial assets. Specialties consist of acting as an adviser, in addition to acquiring or brokering turnkey manufacturing facilities, surplus industrial machinery and equipment, industrial inventories, real estate, and charged-off account receivable portfolios through its two business units: Industrial Assets and Financial Assets.
Yahoo
40 minutes ago
- Yahoo
iSpecimen's $6M Valuation Doesn't Reflect the Business-Let Alone the $200M Treasury (NASDAQ: ISPC)
WOBURN, MA / / August 20, 2025 / A share price of $1.11. A $6.1 million market cap. Just 5.54 million shares outstanding. And a newly announced $200 million digital treasury. On paper, the disconnect between price and intrinsic value, let alone inherent potential, is hard to miss. But the real takeaway isn't just the contrast. It's what that contrast says about iSpecimen Inc. (NASDAQ:ISPC): a company with a functioning platform, measurable revenue, and real-world utility that remains miscategorized and underpriced by the market.(ISPC Share count and price data on 8/20/2025) The digital treasury announcement deserved headlines. It's rare for any microcap, especially in life sciences, to unveil a capital strategy of that scale. But the attention came with a surprising market reaction. Following the news, ISPC shares moved lower. That drop wasn't tied to any breakdown in the business. It was likely due to timing. The news hit after-hours, when retail investors had little access and institutions hadn't yet responded. What the market saw was the number. What it didn't see was the system behind it. Solving the Bottleneck in Life Sciences iSpecimen is not a clinical-stage biotech, nor is it speculative software. It operates a fully functional digital marketplace for human biospecimens-vital inputs for both preclinical and clinical research. The platform allows researchers to efficiently source high-quality, well-characterized specimens with full traceability and regulatory compliance. Blood, plasma, tissue, and genomically sequenced material are the raw materials of discovery, yet sourcing them has long been a fragmented, manual, and inefficient process. iSpecimen fixes that. Its proprietary, cloud-based platform lets researchers search, filter, and request exactly what they need based on disease state, demographic, clinical history, or processing requirements. On the other end, hospitals and labs can monetize excess inventory. iSpecimen handles compliance, logistics, and invoicing. The result is a streamlined transaction that unlocks value for both sides. This isn't a roadmap or beta test. The platform is live, and it's producing revenue. In 2024, the company posted $9.29 million in revenue. That number didn't come from grants or one-time licensing. It came from platform activity, repeated use, and institutional adoption. The Treasury is Not a Gimmick - It's a Strategic Asset The $200 million digital treasury that sparked attention isn't accounted for as cash on the balance sheet. But that doesn't mean it lacks financial weight. It is a capital preservation and liquidity strategy built to support long-term operations. Built on Solana, it features insured custody, cold storage, and a risk-managed structure that removes reliance on traditional capital markets. This isn't a distraction. It's financial insulation. It allows iSpecimen to grow without falling into the trap of repeated, dilutive financing. That kind of flexibility, especially for a microcap, is rare. But while the market focused on that headline, it missed the infrastructure behind it. iSpecimen's core business is still the real story. Expanding Reach Across Critical Therapeutic Areas Behind the scenes, the company is scaling its footprint across several high-value segments of medicine. In cancer research, it's now working with U.S.-based oncology centers and a genomic sequencing partner to deliver hard-to-source biospecimens for precision studies. In women's health, iSpecimen has access to over 600,000 patients through multi-state partnerships, unlocking samples across reproductive, hormone, and breast health. And in early 2025, the company proactively secured sourcing for human metapneumovirus (hMPV), anticipating potential waves of global research interest. Each of these initiatives adds operational depth to a platform that was already delivering. None of it would matter if the core system didn't work. But it does, and the results are increasingly visible. When the Market Doesn't Know Where to Look The mispricing here may stem from the fact that iSpecimen doesn't fit cleanly into a familiar category. It's not chasing regulatory approval, so it doesn't trade on FDA calendars. It's not a SaaS company, though its platform behaves like one. Instead, it sits between logistics, life sciences, and digital infrastructure - and that ambiguity often delays recognition. But that's also where value hides. iSpecimen runs an asset-light, transaction-based model. It doesn't need to build labs or develop its own trial pipeline. It monetizes what already exists by organizing and standardizing the connections between researchers and providers. That model is scalable across disease areas, institutions, and even global geographies. This Isn't a Bet. It's a Repricing in Progress The treasury may have been the headline, but it isn't the whole story. It's simply a structural advantage layered onto a business that is already performing. The marketplace, the revenue, the partnerships, and the platform all existed before the $200 million plan was announced. Thus, ISPC isn't a company hoping for validation. It's a company that already has it - just not from the market yet. At $1.11, the share price reflects none of that. But that doesn't mean the value isn't there. It just means the recognition hasn't arrived yet. When it does, the most temporary number in this entire story might be the one investors are staring at right now. *Reprinted with permission from Hawk Point Media Group, LLC. About iSpecimen iSpecimen (NASDAQ: ISPC) offers an online marketplace for human biospecimens, connecting scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers and other healthcare organizations. For more information, please visit Forward-Looking Statements This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risk factors contained in the Company's filings with the SEC, which are available for review at Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company's forward-looking statements occurs, the Company's business, financial condition and operating results may vary materially from those expressed in the Company's forward-looking statements. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please contact:Investor Contactsinfo@ For this content only: info@ Disclaimers: This presentation has been created by Hawk Point Media Group, Llc. (HPM) and is responsible for the production and distribution of this content. This presentation should be considered and explicitly regarded as sponsored content. Hawk Point Media Group, LLC. has been compensated five thousand dollars to create this content as part of a more extensive digital marketing program by IR Agency, Inc. Accordingly, this content may be reused and syndicated beyond the channels used by Hawk Point Media, LLC. This disclaimer and the link to the broader disclosures must be part of all reproductions. That compensation creates a conflict of interest because the content presented may only provide a favorable viewpoint of the company featured. The contributors do NOT buy and sell securities before and after any article, report, or publication. HPM holds ZERO shares and has never owned stock in iSpecimen Inc. The information in this video, article, and related newsletters is not intended to be, nor does it constitute, investment advice or recommendations. Hawk Point Media Group, Llc. strongly urges you to conduct a complete and independent investigation of the respective companies and consider all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. Never take opinions, articles presented, or content provided as the sole reason to invest in any featured company. Investors must always perform their own due diligence before investing in any publicly traded company and understand the risks involved, including losing their entire investment. SOURCE: iSpecimen, Inc. View the original press release on ACCESS Newswire Sign in to access your portfolio
